​vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company's future growth.

Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.

The WHO's latest decision is based on advice from an independent panel of experts who evaluated data from 16 randomized controlled studies.

Surrozen's ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.

Proof of concept for the Genetically Engineered Microbial Medicines (GEMM) platform came in a recent first-in-human, Phase I trial.

Life sciences professionals are mixed as to whether the job market is in favor of the candidate or the employer. However, life sciences employers aren’t.

Bayer has high hopes of driving its prostate cancer drug into blockbuster status, meaning over $1 billion in annual sales. This week's ARASENS trial results should help pave the road.

The SEC announced charges against Usama Malik and his former live-in girlfriend Lauren S. Wood regarding an FDA decision during a trading black out.

This afternoon, the U.S. Food and Drug Administration expanded the Emergency Use Authorization for Eli Lilly’s monoclonal antibody treatment combination of bamlanivimab and etesevimab.

​Scientists from Cardiff University and the Arizona State University believe they have found the likely cause of blood clotting in some recipients of the Oxford-AstraZeneca COVID-19 vaccine.

​Called "iBlastoids," the alternative embryo-like structures are grown for up to 13 days in the lab for use in different types of studies on the behavior of human embryos.

Researchers from Harvard University and the U.S. Department of Veterans Affairs (VA) found that the Moderna mRNA vaccine was slightly better than the Pfizer-BioNTech vaccine.

Two years into the COVID-19 pandemic, countries are reporting the fourth wave of rising cases, driven mainly by the Delta variant, although Omicron has everybody concerned. Here’s a look.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

Novartis held an investor event to discuss their research programs, highlighting its partnership with Belgian pharma company UCB worth up to $1.5 billion.

With this new collaboration, Astellas will take advantage of Dynos' next-gen AAV vectors to deliver its gene therapy.

Research continues to reveal how COVID-19 affects different people with different health issues, both short-term and long-term.

​The Phase III DISCREET study evaluated the efficacy of Otezla (apremilast) in adults who have been diagnosed with moderate to severe plaque psoriasis and moderate to severe genital psoriasis.